Head-to-head evidence
Umeclidinium vs Umeclidinium/Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT02184611 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).
Next expected readout: December 2026 · NCT07133880 (registry estimate)
Umeclidinium/Vilanterol
Marketed by GlaxoSmithKline
NCT01777334 · Phase 3 · completed
The trial randomly assigned 905 participants and used double blinding with tiotropium as an active comparator. Its primary endpoint was the clinical lung-function measure trough FEV1, and the primary comparison significantly favored umeclidinium/vilanterol.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Umeclidinium's landscape · Umeclidinium/Vilanterol's landscape